Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Only 8 trading days left now until 145,000,000 warrant expire. Will be interesting to see what Mat does here. Again, the reason given to extend the .6p warrants doesn't apply to the .35p warrants so it will need to be a new reason. The company is cash flow positive, oil prices going back up, then don't extend. DYOR.
30 days left until 1450,000,000 warrants expire.
Will be interesting to see if Matt allows an extension on these. The reason given for the .6p warrants doesn't really apply for the .35p warrants as there has been plenty of time that the SP has been way above .35p to exercise.
Before Billy and the crew start beefing, save your breath I'm positing this just so people are aware, not to create a debate - not interested in arguments.
145,000,000 warrants @.35p expire in 56 days time. Won't be exercised at this price of course. Understand the concern some might hold about whether they're extended or not. I'd hope not as the reasoning on the .6p warrants will not be applicable for the .35 batch.
Good level to accumulate down here, I've been buying.
GLA
Disappointing news there but those are the risks with oilers. Drop overdone, £3.5m market cap for a profitable oil producer in these times is insane. This bounces from here imo. Increased my holding on the drop.
I wouldn't hedge anything. Production is not increasing enough demand is growing and will continue to grow especially when China comes online. Facts are, there's not enough oil in the system and I fully expect WTI to push $130 as a minimum.
Polarean Imaging has technology which greatly (50x) improves the resolution of lung imaging scanning. It submitted it FDA application and received a CRL decline letter in October 2021. The reason for the decline is because the company changed manufacturer during the application process and so the application wasn't technically correct.
After 6 months of working on their re-submission this was submitted last month. The FDA accepted their re-submission as valid (in that they've addressed the FDA's concerns) and the FDA will provide a response in September as to whether they grant FDA clearance or not.
Before the CRL in October 2021 the SP shot up to 106.5p before the CRL saw it crash down to a low of 42p. Directors all bought material amounts following this at 47p-53p providing confidence that they believe they will get FDA clearance.
Company is well cashed up having $28m as of December 2021.
for the last 6 months the SP has been trading in a range of 50p-60p.
Thesis: SP rose in anticipation of FDA clearance last time to 106.5p. Directors bought after the CRL decline letter at similar prices to those on offer today. Company took their time with their re-submission and this is expected in September 2022. As such, I believe, just like the first time, the SP will rise as we get closer to the September deadline. I'm not sure it will get back to 106.p but 80p is in my view a very realistic prospect. Build position before the excitement starts and then get out BEFORE the FDA decision is the plan. Looking for circa 50% return before the end of August.